11/20
08:02 am
mira
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site [Yahoo! Finance]
High
Report
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site [Yahoo! Finance]
11/20
07:44 am
mira
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
High
Report
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
10/28
07:30 am
mira
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Medium
Report
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
10/21
07:30 am
mira
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
High
Report
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
10/2
05:59 am
mira
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Low
Report
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
9/30
01:04 pm
mira
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
9/27
07:30 am
mira
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Medium
Report
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
9/18
07:00 am
mira
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
High
Report
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
9/11
07:46 am
mira
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA [Yahoo! Finance]
Medium
Report
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA [Yahoo! Finance]
9/11
07:30 am
mira
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Medium
Report
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
8/26
08:00 am
mira
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
High
Report
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study